vs
ExlService Holdings, Inc.（EXLS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是ExlService Holdings, Inc.的1.4倍（$772.1M vs $542.6M），Revvity净利率更高（12.7% vs 11.1%，领先1.6%），ExlService Holdings, Inc.同比增速更快（12.7% vs 5.9%），Revvity自由现金流更多（$161.8M vs $106.5M），过去两年ExlService Holdings, Inc.的营收复合增速更高（11.5% vs 9.0%）
ExlService Holdings Inc.是全球知名的分析与数字解决方案服务商，服务覆盖保险、医疗健康、银行金融服务、媒体、零售等多个行业，总部位于纽约，在美国、欧洲、亚洲、拉美、澳大利亚、南非等地拥有超过5.4万名专业从业人员。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
EXLS vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$542.6M
营收增速更快
EXLS
高出6.9%
5.9%
净利率更高
RVTY
高出1.6%
11.1%
自由现金流更多
RVTY
多$55.3M
$106.5M
两年增速更快
EXLS
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $542.6M | $772.1M |
| 净利润 | $60.2M | $98.4M |
| 毛利率 | 38.6% | — |
| 营业利润率 | 14.4% | 14.5% |
| 净利率 | 11.1% | 12.7% |
| 营收同比 | 12.7% | 5.9% |
| 净利润同比 | 18.9% | 3.9% |
| 每股收益（稀释后） | $0.38 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXLSRVTY
| Q4 25 | $542.6M | $772.1M | ||
| Q3 25 | $529.6M | $698.9M | ||
| Q2 25 | $514.5M | $720.3M | ||
| Q1 25 | $501.0M | $664.8M | ||
| Q4 24 | $481.4M | $729.4M | ||
| Q3 24 | $472.1M | $684.0M | ||
| Q2 24 | $448.4M | $691.7M | ||
| Q1 24 | $436.5M | $649.9M |
净利润EXLSRVTY
| Q4 25 | $60.2M | $98.4M | ||
| Q3 25 | $58.2M | $46.7M | ||
| Q2 25 | $66.1M | $53.9M | ||
| Q1 25 | $66.6M | $42.2M | ||
| Q4 24 | $50.7M | $94.6M | ||
| Q3 24 | $53.0M | $94.4M | ||
| Q2 24 | $45.8M | $55.4M | ||
| Q1 24 | $48.8M | $26.0M |
毛利率EXLSRVTY
| Q4 25 | 38.6% | — | ||
| Q3 25 | 38.5% | 53.6% | ||
| Q2 25 | 37.7% | 54.5% | ||
| Q1 25 | 38.6% | 56.5% | ||
| Q4 24 | 38.1% | — | ||
| Q3 24 | 37.8% | 56.3% | ||
| Q2 24 | 37.1% | 55.7% | ||
| Q1 24 | 37.4% | 54.6% |
营业利润率EXLSRVTY
| Q4 25 | 14.4% | 14.5% | ||
| Q3 25 | 14.4% | 11.7% | ||
| Q2 25 | 15.8% | 12.6% | ||
| Q1 25 | 15.7% | 10.9% | ||
| Q4 24 | 14.8% | 16.3% | ||
| Q3 24 | 14.7% | 14.3% | ||
| Q2 24 | 13.7% | 12.4% | ||
| Q1 24 | 14.1% | 6.8% |
净利率EXLSRVTY
| Q4 25 | 11.1% | 12.7% | ||
| Q3 25 | 11.0% | 6.7% | ||
| Q2 25 | 12.8% | 7.5% | ||
| Q1 25 | 13.3% | 6.4% | ||
| Q4 24 | 10.5% | 13.0% | ||
| Q3 24 | 11.2% | 13.8% | ||
| Q2 24 | 10.2% | 8.0% | ||
| Q1 24 | 11.2% | 4.0% |
每股收益（稀释后）EXLSRVTY
| Q4 25 | $0.38 | $0.86 | ||
| Q3 25 | $0.36 | $0.40 | ||
| Q2 25 | $0.40 | $0.46 | ||
| Q1 25 | $0.40 | $0.35 | ||
| Q4 24 | $0.31 | $0.77 | ||
| Q3 24 | $0.33 | $0.77 | ||
| Q2 24 | $0.28 | $0.45 | ||
| Q1 24 | $0.29 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $328.4M | $919.9M |
| 总债务越低越好 | $298.6M | — |
| 股东权益账面价值 | $912.7M | $7.3B |
| 总资产 | $1.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资EXLSRVTY
| Q4 25 | $328.4M | $919.9M | ||
| Q3 25 | $390.1M | $931.4M | ||
| Q2 25 | $353.3M | $991.8M | ||
| Q1 25 | $331.4M | $1.1B | ||
| Q4 24 | $340.6M | $1.2B | ||
| Q3 24 | $325.8M | $1.2B | ||
| Q2 24 | $276.1M | $2.0B | ||
| Q1 24 | $246.2M | $1.7B |
总债务EXLSRVTY
| Q4 25 | $298.6M | — | ||
| Q3 25 | $354.8M | — | ||
| Q2 25 | $260.0M | — | ||
| Q1 25 | $307.3M | — | ||
| Q4 24 | $288.5M | — | ||
| Q3 24 | $344.7M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EXLSRVTY
| Q4 25 | $912.7M | $7.3B | ||
| Q3 25 | $952.4M | $7.4B | ||
| Q2 25 | $1.1B | $7.6B | ||
| Q1 25 | $1.0B | $7.6B | ||
| Q4 24 | $929.9M | $7.7B | ||
| Q3 24 | $907.6M | $7.9B | ||
| Q2 24 | $852.6M | $7.9B | ||
| Q1 24 | $803.3M | $7.8B |
总资产EXLSRVTY
| Q4 25 | $1.7B | $12.2B | ||
| Q3 25 | $1.7B | $12.1B | ||
| Q2 25 | $1.7B | $12.4B | ||
| Q1 25 | $1.7B | $12.4B | ||
| Q4 24 | $1.6B | $12.4B | ||
| Q3 24 | $1.6B | $12.8B | ||
| Q2 24 | $1.5B | $13.4B | ||
| Q1 24 | $1.4B | $13.4B |
负债/权益比EXLSRVTY
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $106.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 19.6% | 21.0% |
| 资本支出强度资本支出/营收 | 2.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.95× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $298.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流EXLSRVTY
| Q4 25 | $117.4M | $182.0M | ||
| Q3 25 | $120.7M | $138.5M | ||
| Q2 25 | $109.4M | $134.3M | ||
| Q1 25 | $3.2M | $128.2M | ||
| Q4 24 | $105.3M | $174.2M | ||
| Q3 24 | $110.1M | $147.9M | ||
| Q2 24 | $74.9M | $158.6M | ||
| Q1 24 | $-21.9M | $147.6M |
自由现金流EXLSRVTY
| Q4 25 | $106.5M | $161.8M | ||
| Q3 25 | $106.4M | $120.0M | ||
| Q2 25 | $95.0M | $115.5M | ||
| Q1 25 | $-9.7M | $112.2M | ||
| Q4 24 | $95.3M | $149.8M | ||
| Q3 24 | $97.3M | $125.6M | ||
| Q2 24 | $62.8M | $136.6M | ||
| Q1 24 | $-33.1M | $129.7M |
自由现金流率EXLSRVTY
| Q4 25 | 19.6% | 21.0% | ||
| Q3 25 | 20.1% | 17.2% | ||
| Q2 25 | 18.5% | 16.0% | ||
| Q1 25 | -1.9% | 16.9% | ||
| Q4 24 | 19.8% | 20.5% | ||
| Q3 24 | 20.6% | 18.4% | ||
| Q2 24 | 14.0% | 19.7% | ||
| Q1 24 | -7.6% | 20.0% |
资本支出强度EXLSRVTY
| Q4 25 | 2.0% | 2.6% | ||
| Q3 25 | 2.7% | 2.6% | ||
| Q2 25 | 2.8% | 2.6% | ||
| Q1 25 | 2.6% | 2.4% | ||
| Q4 24 | 2.1% | 3.4% | ||
| Q3 24 | 2.7% | 3.3% | ||
| Q2 24 | 2.7% | 3.2% | ||
| Q1 24 | 2.6% | 2.7% |
现金转化率EXLSRVTY
| Q4 25 | 1.95× | 1.85× | ||
| Q3 25 | 2.08× | 2.97× | ||
| Q2 25 | 1.66× | 2.49× | ||
| Q1 25 | 0.05× | 3.03× | ||
| Q4 24 | 2.08× | 1.84× | ||
| Q3 24 | 2.08× | 1.57× | ||
| Q2 24 | 1.63× | 2.87× | ||
| Q1 24 | -0.45× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXLS
| Insurance | $185.8M | 34% |
| Healthcare And Life Sciences | $142.2M | 26% |
| Banking Capital Markets And Diversified Industries | $122.6M | 23% |
| International Growth Markets | $92.0M | 17% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
